JEFFREY HOLT, MD
Medical Practice at 16 Ave, Denver, CO
License number
Colorado 40487
Category
Medical Practice
Type
Anatomic Pathology & Clinical Pathology
Address
Address
12605 E 16Th Ave, Denver, CO 80045
Phone
(720) 848-0000
(303) 493-7000
(303) 493-7000
Professional information
Dr. Jeffrey Holt, Aurora CO - MD (Doctor of Medicine)
Specialties:
Anatomic & Clinical Pathology
Address:
12605 E 16 Ave, Aurora 80045
(720) 848-0000 (Phone)
UNIVERSITY OF COLORADO AT DENVER
12631 E 17 Ave, Aurora 80045
(720) 848-0000 (Phone), (303) 724-3712 (Fax)
(720) 848-0000 (Phone)
UNIVERSITY OF COLORADO AT DENVER
12631 E 17 Ave, Aurora 80045
(720) 848-0000 (Phone), (303) 724-3712 (Fax)
Certifications:
Anatomic & Clinical Pathology, 1983
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Mi Med Sch
Graduated: 1979
U Rochester
National Institutes Of Health Clinical Center
University of Mi Med Sch
Graduated: 1979
U Rochester
National Institutes Of Health Clinical Center
Jeffrey T Holt, Aurora CO
Specialties:
Pathologist
Address:
13611 E Colfax Ave, Aurora, CO 80045
Education:
University of Michigan, Medical School - Doctor of Medicine
Strong Memorial Hospital - Residency - Pathology
Strong Memorial Hospital - Residency - Pathology
Board certifications:
American Board of Pathology Certification in Clinical Pathology (Pathology)
Compositions And Methods For Tissue-Based Protein Truncation Test For Disease Diagnosis
US Patent:
2010003, Feb 11, 2010
Filed:
Sep 25, 2007
Appl. No.:
12/442771
Inventors:
Jeffrey T. Holt - Aurora CO, US
International Classification:
G01N 33/574, G01N 33/53, C07K 16/00
US Classification:
435 723, 435 721, 5303871
Abstract:
Embodiments herein concern methods and compositions for diagnosing or predicting the onset of a genetic disorder In certain embodiments, the methods may include use of a rapid and inexpensive assay. In other embodiments, the assay utilizes a tissue sample from a subject to identify the state of a target protein known to associate with a genetic disorder In accordance with these embodiments, the target protein may have a DNA sequence change such as a mutation, deletion, insertion or substitution leading to generation of a termination codon and truncation of the protein. In some embodiments, a composition of an antibody directed to bind a protein associated with a disorder may be used to predict onset of the disorder or predict sensitivity of the disorder to therapeutic treatments.
Systems Test At Lockheed Martin Space Systems Company
Position:
Systems Test at Lockheed Martin Space Systems Company
Location:
Greater Denver Area
Industry:
Defense & Space
Work:
Lockheed Martin Space Systems Company
-
Systems Test
Compositions, Methods And Uses For Modulation Of Brca 1
US Patent:
2012004, Feb 16, 2012
Filed:
Apr 13, 2009
Appl. No.:
12/937217
Inventors:
Jeffrey Thomas Holt - Aurora CO, US
Steve Anderson - Denver CO, US
Andrew Cook Nelson - St. Paul CO, US
Steve Anderson - Denver CO, US
Andrew Cook Nelson - St. Paul CO, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF COLORADO - Denver CO
International Classification:
A61K 38/17, A61K 38/30, A61P 35/00, A61K 31/404, A61K 31/663, C07K 16/18, A61K 38/28
US Classification:
514 59, 5303879, 514 86, 514 193, 514414, 514102, 514 194, 514 195
Abstract:
Embodiments of the present invention generally relate to methods, compositions and uses for diagnosis and treatment of cancer. Certain embodiments report methods and compositions for diagnosing and/or treating a subject having a BRCA1-related cancer or sporadic cancer. Some embodiments disclose treatments that can include, but are not limited to, modulation of BRCA1. In some embodiments, methods for identifying a subject with unstable BRCA1 protein are reported.